Yttrium-90 besilesomab - TheraPharm
Alternative Names: 90Y-anti-CD66-MTR; Y-90-anti-CD66; Yttrium-90 labelled anti-CD66 monoclonal antibodyLatest Information Update: 28 Sep 2022
At a glance
- Originator TheraPharm
- Developer Great Ormond Street Hospital; University Hospital Southampton NHS Foundation Trust
- Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Haematological malignancies
- No development reported Leukaemia
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Leukaemia(In adolescents, In children, In infants, In neonates, Second-line therapy or greater) in United Kingdom (IV, Infusion)
- 29 Apr 2021 Great Ormond Street Hospital for Children NHS Foundation Trust plans a phase II trial for Leukaemia (In adolescents, In children) in June 2021 (Parenteral) (NCT04856215)
- 30 Nov 2020 Yttrium-90 besilesomab receives Orphan Drug status for Haematological malignancies in European Union before November 2020